Corbus Pharmaceuticals Stock (NASDAQ: CRBP)

Corbus Pharmaceuticals

CORBUS PHARMACEUTICALS HOLDI

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

CRBP

Biotech

News

Health Care

General

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate

AI-Generated Image

Cannabis

Price Target

Reiteration

Markets

Analyst Ratings

Trading Ideas

Corbus Pharmaceuticals received buy ratings from H.C. Wainwright and Oppenheimer, citing the company&#39;s diversified pipeline.

Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say &#39;Buy The Dip&#39; Now

Analyst Color

Movers

SKYE

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose. However, investors reacted to limited gains at higher doses. Corbus Pharmaceuticals and Skye Bioscience stocks dropped as all three companies explore CB1 inhibition in obesity treatment.

Novo Nordisk&#39;s Monlunabant Data Drags Stocks Of Smaller Players

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

Press Releases

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Earnings

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Management

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

AKTX

QURE

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adagene Inc. - ADS, each representing 1.25 ordinary shares

Adagene

Anixa Biosciences

Atossa Therapeutics

Biomea Fusion

BeyondSpring

C4 Therapeutics

Coherus Oncology

Climb Bio

Coya Therapeutics

Genelux

HilleVax

TuHURA Biosciences

Insight Molecular Diagnostics Inc. - Common Stock

Insight Molecular

Immuneering Corporation - Class A Common Stock

Immuneering

IO Biotech

Invivyd

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

OKYO Pharma

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Tenaya Therapeutics

Vor Biopharma

Whitehawk Therapeutics, Inc. - Common Stock

Whitehawk Therapeutics

XBiotech

Zentalis Pharmaceuticals, Inc. - common stock

Zentalis Pharma

RBC Capital

Oppenheimer

HC Wainwright & Co.

Jefferies

Comments

Corbus Pharmaceuticals

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell